Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy

Breast

Volumn 16, Issue 5, 2007, Pages 482-488

  Akashi Tanaka, Sadako ^a   Omatsu, Mutsuko ^b,c   Shimizu, Chikako ^a   Ando, Masashi ^a   Terada, Kotoe ^a   Shien, Tadahiko ^a   Kinoshita, Takayuki ^a   Fujiwara, Yasuhiro ^a   Seki, Kunihiko ^b   Hasegawa, Tadashi ^b,c   Fukutomi, Takashi ^a,d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Ki 67; Neoadjuvant endocrine therapy; Pathological response; Prognostic factor

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 34848917561     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.02.003     Document Type: Article

References (17)

1. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 22 (2005) 5108-5116
2. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
3. Semiglazov V.F., Semiglazov V.V., Ivanov V.G., et al. Neoadjuvant endocrine therapy: exemestane(E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients. Breast Cancer Res Treat 82 Suppl 1 (2003) S22
4. Cataliotti L., Buzdar A., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "Arimidex" compared to Tamoxifen (PROACT) trial. Cancer 106 6 (2006) 2095-2103
5. Dixon J.M. Role of endocrine therapy in the neoadjuvant surgical setting. Ann Surg Oncol 11 1 Suppl (2004) 18S-23S
6. Ellis M.J. Neoadjuvant endocrine therapy for breast cancer: more questions than answers. J Clin Oncol 23 22 (2005) 4842-4844
7. Dowsett M., Smith I.E., Ebbs S.R., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11 (2005) 951s-958s
8. Tao Y., Klause A., Vickers A., et al. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 95 (2005) 91-95
9. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 3 (2000) 205-216
10. Johnston S.R., Boeddinghaus I.M., Riddler S., et al. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res 59 15 (1999) 3646-3651
11. Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer 2005. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 12 Suppl (2005) s12
12. Fisher B., Bryant J., Wolmark N., Mamounas E., and Brown A. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
13. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23 28 (2005) 7212-7220
14. Kaufmann M., von Minckwitz G., and Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14 6 (2005) 576-581
15. Chang J., Powles T.J., Allred D.C., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17 10 (1999) 3058-3063
16. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
17. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 23 (2006) 3726-3734